BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 15, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tetravalent dengue vaccine: Phase III started

sanofi-aventis' Sanofi Pasteur S.A. vaccines division began an Australian Phase III trial to evaluate subcutaneous tetravalent dengue vaccine in 715 healthy volunteers....

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >